NEOPLASMS MALIGNANT

Clinical trials for NEOPLASMS MALIGNANT explained in plain language.

Never miss a new study

Get alerted when new NEOPLASMS MALIGNANT trials appear

Sign up with your email to follow new studies for NEOPLASMS MALIGNANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1 Completed 1

New Dual-Action antibody enters first human trials for Hard-to-Treat cancers

Disease control Not yet recruiting

This early-phase study tests a new drug called SIM0689 in adults with advanced solid tumors that have stopped responding to standard treatments. SIM0689 is a bispecific antibody designed to block two cancer-promoting pathways (PD1 and VEGF). The trial will first find a safe dose,…

Matched conditions: NEOPLASMS MALIGNANT

Phase: PHASE1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control

Last updated Jun 27, 2026 14:01 UTC

NEOPLASMS MALIGNANT

Get alerted when new NEOPLASMS MALIGNANT trials appear

New Dual-Action antibody enters first human trials for Hard-to-Treat cancers